In the most severe presentations of retinal vasculitis — with significant loss of visual acuity, macular edema, and extensive retinal involvement — systemic corticosteroid therapy is the initial treatment. When corticosteroids fail to achieve adequate disease control, a defined next-line approach is indicated.
Severe retinal vasculitis presenting with significant loss of visual acuity, macular edema, and extensive retinal involvement — cases at the severe end of the spectrum that require escalation beyond corticosteroid therapy.
Systemic corticosteroid therapy (oral or intravenous) was used as first-line treatment for severe disease. This protocol applies when corticosteroids have not achieved the primary goal: suppression of intraocular inflammation (disease control).
The next step centres on systemic immunosuppressant therapy. Several agents within this class may be considered depending on individual patient factors. The full protocol identifies which agents are relevant, under what conditions, and includes all additional clinical guidance.
Suppression of intraocular inflammation. Immunosuppressants may take up to 3 months to take effect.